Multiple Sclerosis-Pipeline Review, H2 2016

Multiple Sclerosis-Pipeline Review, H2 2016


  • Products Id :- GMDHC8845IDB
  • |
  • Pages: 928
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Global Markets Direct’s, ‘Multiple Sclerosis - Pipeline Review, H2 2016’, provides an overview of the Multiple Sclerosis pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Multiple Sclerosis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Multiple Sclerosis and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

 

Scope

 

The report provides a snapshot of the global therapeutic landscape of Multiple Sclerosis

The report reviews pipeline therapeutics for Multiple Sclerosis by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Multiple Sclerosis therapeutics and enlists all their major and minor projects

The report assesses Multiple Sclerosis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Multiple Sclerosis

 

Reasons to Buy

 

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Multiple Sclerosis

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Multiple Sclerosis pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

Introduction 10

Multiple Sclerosis Overview 11

Therapeutics Development 12

Multiple Sclerosis - Therapeutics under Development by Companies 14

Multiple Sclerosis - Therapeutics under Investigation by Universities/Institutes 31

Multiple Sclerosis - Pipeline Products Glance 34

Multiple Sclerosis - Products under Development by Companies 38

Multiple Sclerosis - Products under Investigation by Universities/Institutes 58

Multiple Sclerosis - Companies Involved in Therapeutics Development 62

Multiple Sclerosis - Therapeutics Assessment 250

Drug Profiles 291

Multiple Sclerosis - Dormant Projects 839

Multiple Sclerosis - Discontinued Products 864

Multiple Sclerosis - Product Development Milestones 869

Appendix 891

List of Figures

Number of Products under Development for Multiple Sclerosis, H2 2016 48

Number of Products under Development for Multiple Sclerosis - Comparative Analysis, H2 2016 49

Number of Products under Development by Companies, H2 2016 50

Number of Products under Investigation by Universities/Institutes, H2 2016 67

Comparative Analysis by Late Stage Development, H2 2016 70

Comparative Analysis by Clinical Stage Development, H2 2016 71

Comparative Analysis by Early Stage Products, H2 2016 72

Assessment by Monotherapy Products, H2 2016 286

Number of Products by Top 10 Targets, H2 2016 288

Number of Products by Stage and Top 10 Targets, H2 2016 288

Number of Products by Top 10 Mechanism of Actions, H2 2016 304

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016 304

Number of Products by Top 10 Routes of Administration, H2 2016 323

Number of Products by Stage and Top 10 Routes of Administration, H2 2016 323

Number of Products by Top 10 Molecule Types, H2 2016 325

Number of Products by Stage and Top 10 Molecule Types, H2 2016 325

Number of Products under Development for Multiple Sclerosis, H2 2016 48

Number of Products under Development for Multiple Sclerosis - Comparative Analysis, H2 2016 49

Number of Products under Development by Companies, H2 2016 51

Number of Products under Development by Companies, H2 2016 (Contd..1) 52

Number of Products under Development by Companies, H2 2016 (Contd..2) 53

Number of Products under Development by Companies, H2 2016 (Contd..3) 54

Number of Products under Development by Companies, H2 2016 (Contd..4) 55

Number of Products under Development by Companies, H2 2016 (Contd..5) 56

Number of Products under Development by Companies, H2 2016 (Contd..6) 57

Number of Products under Development by Companies, H2 2016 (Contd..7) 58

Number of Products under Development by Companies, H2 2016 (Contd..8) 59

Number of Products under Development by Companies, H2 2016 (Contd..9) 60

Number of Products under Development by Companies, H2 2016 (Contd..10) 61

Number of Products under Development by Companies, H2 2016 (Contd..11) 62

Number of Products under Development by Companies, H2 2016 (Contd..12) 63

Number of Products under Development by Companies, H2 2016 (Contd..13) 64

Number of Products under Development by Companies, H2 2016 (Contd..14) 65

Number of Products under Development by Companies, H2 2016 (Contd..15) 66

Number of Products under Investigation by Universities/Institutes, H2 2016 67

Number of Products under Investigation by Universities/Institutes, H2 2016 (Contd..1) 68

Number of Products under Investigation by Universities/Institutes, H2 2016 (Contd..2) 69

Comparative Analysis by Late Stage Development, H2 2016 70

Comparative Analysis by Clinical Stage Development, H2 2016 71

Comparative Analysis by Early Stage Development, H2 2016 72

Comparative Analysis by Unknown Stage Development, H2 2016 73

Products under Development by Companies, H2 2016 74

Products under Development by Companies, H2 2016 (Contd..1) 75

Products under Development by Companies, H2 2016 (Contd..2) 76

Products under Development by Companies, H2 2016 (Contd..3) 77

Products under Development by Companies, H2 2016 (Contd..4) 78

Products under Development by Companies, H2 2016 (Contd..5) 79

Products under Development by Companies, H2 2016 (Contd..6) 80

Products under Development by Companies, H2 2016 (Contd..7) 81

Products under Development by Companies, H2 2016 (Contd..8) 82

Products under Development by Companies, H2 2016 (Contd..9) 83

Products under Development by Companies, H2 2016 (Contd..10) 84

Products under Development by Companies, H2 2016 (Contd..11) 85

Products under Development by Companies, H2 2016 (Contd..12) 86

Products under Development by Companies, H2 2016 (Contd..13) 87

Products under Development by Companies, H2 2016 (Contd..14) 88

Products under Development by Companies, H2 2016 (Contd..15) 89

Products under Development by Companies, H2 2016 (Contd..16) 90

Products under Development by Companies, H2 2016 (Contd..17) 91

Products under Development by Companies, H2 2016 (Contd..18) 92

Products under Development by Companies, H2 2016 (Contd..19) 93

Products under Investigation by Universities/Institutes, H2 2016 94

Products under Investigation by Universities/Institutes, H2 2016 (Contd..1) 95

Products under Investigation by Universities/Institutes, H2 2016 (Contd..2) 96

Products under Investigation by Universities/Institutes, H2 2016 (Contd..3) 97

Multiple Sclerosis - Pipeline by 2-BBB Medicines BV, H2 2016 98

Multiple Sclerosis - Pipeline by 4D Pharma Plc, H2 2016 99

Multiple Sclerosis - Pipeline by AB Science SA, H2 2016 100

Multiple Sclerosis - Pipeline by AbbVie Inc, H2 2016 101

Multiple Sclerosis - Pipeline by Abion Inc, H2 2016 102

Multiple Sclerosis - Pipeline by Ablynx NV, H2 2016 103

Multiple Sclerosis - Pipeline by Abzena Plc, H2 2016 104

Multiple Sclerosis - Pipeline by Acorda Therapeutics Inc, H2 2016 105

Multiple Sclerosis - Pipeline by Actelion Ltd, H2 2016 106

Multiple Sclerosis - Pipeline by Adamas Pharmaceuticals Inc, H2 2016 107

Multiple Sclerosis - Pipeline by Addex Therapeutics Ltd, H2 2016 108

Multiple Sclerosis - Pipeline by Adhaere Pharmaceuticals Inc, H2 2016 109

Multiple Sclerosis - Pipeline by Aegis Therapeutics LLC, H2 2016 110

Multiple Sclerosis - Pipeline by Affectis Pharmaceuticals AG, H2 2016 111

Multiple Sclerosis - Pipeline by AiCuris GmbH & Co KG, H2 2016 112

Multiple Sclerosis - Pipeline by Alkermes Plc, H2 2016 113

Multiple Sclerosis - Pipeline by Alpha Cancer Technologies Inc, H2 2016 114

Multiple Sclerosis - Pipeline by Amarna Therapeutics BV, H2 2016 115

Multiple Sclerosis - Pipeline by Anavex Life Sciences Corp, H2 2016 116

Multiple Sclerosis - Pipeline by Antisense Therapeutics Ltd, H2 2016 117

Multiple Sclerosis - Pipeline by Aphios Corp, H2 2016 118

Multiple Sclerosis - Pipeline by Apitope International NV, H2 2016 119

Multiple Sclerosis - Pipeline by ARA Healthcare Pvt Ltd, H2 2016 120

Multiple Sclerosis - Pipeline by Arena Pharmaceuticals Inc, H2 2016 121

Multiple Sclerosis - Pipeline by arGEN-X BV, H2 2016 122

Multiple Sclerosis - Pipeline by Argos Therapeutics Inc, H2 2016 123

Multiple Sclerosis - Pipeline by Arrien Pharmaceuticals LLC, H2 2016 124

Multiple Sclerosis - Pipeline by Artielle ImmunoTherapeutics Inc, H2 2016 125

Multiple Sclerosis - Pipeline by Astellas Pharma Inc, H2 2016 126

Multiple Sclerosis - Pipeline by Asterias Biotherapeutics Inc, H2 2016 127

Multiple Sclerosis - Pipeline by Atara Biotherapeutics Inc, H2 2016 128

Multiple Sclerosis - Pipeline by Athersys Inc, H2 2016 129

Multiple Sclerosis - Pipeline by Atlantic Bio Sci LLC, H2 2016 130

Multiple Sclerosis - Pipeline by Axxam SpA, H2 2016 131

Multiple Sclerosis - Pipeline by Baliopharm AG, H2 2016 132

Multiple Sclerosis - Pipeline by Bio-Cancer Treatment International Ltd, H2 2016 133

Multiple Sclerosis - Pipeline by BioAegis Therapeutics Inc, H2 2016 134

Multiple Sclerosis - Pipeline by BioApex sro, H2 2016 135

Multiple Sclerosis - Pipeline by Biocad, H2 2016 136

Multiple Sclerosis - Pipeline by Biocon Ltd, H2 2016 137

Multiple Sclerosis - Pipeline by Biogen Inc, H2 2016 138

Multiple Sclerosis - Pipeline by Biogenomics Ltd, H2 2016 139

Multiple Sclerosis - Pipeline by BioHealthonomics Inc, H2 2016 140

Multiple Sclerosis - Pipeline by Biokine Therapeutics Ltd, H2 2016 141

Multiple Sclerosis - Pipeline by Biomar Microbial Technologies, H2 2016 142

Multiple Sclerosis - Pipeline by Bioncotech Therapeutics SL, H2 2016 143

Multiple Sclerosis - Pipeline by Bionovis SA, H2 2016 144

Multiple Sclerosis - Pipeline by Bionure Farma SL, H2 2016 145

Multiple Sclerosis - Pipeline by Biovista Inc, H2 2016 146

Multiple Sclerosis - Pipeline by Bolder Biotechnology Inc, H2 2016 147

Multiple Sclerosis - Pipeline by BrainStorm Cell Therapeutics Inc, H2 2016 148

Multiple Sclerosis - Pipeline by Bristol-Myers Squibb Company, H2 2016 149

Multiple Sclerosis - Pipeline by C4X Discovery Holdings PLC, H2 2016 150

Multiple Sclerosis - Pipeline by CASI Pharmaceuticals Inc, H2 2016 151

Multiple Sclerosis - Pipeline by Catalyst Pharmaceuticals Inc, H2 2016 152

Multiple Sclerosis - Pipeline by Celgene Corp, H2 2016 153

Multiple Sclerosis - Pipeline by Cell Cure Neurosciences Ltd, H2 2016 154

Multiple Sclerosis - Pipeline by Cell2B Advanced Therapeutics SA, H2 2016 155

Multiple Sclerosis - Pipeline by Cellceutix Corp, H2 2016 156

Multiple Sclerosis - Pipeline by Cognosci Inc, H2 2016 157

Multiple Sclerosis - Pipeline by Coherus BioSciences Inc, H2 2016 158

Multiple Sclerosis - Pipeline by Commence Bio Inc, H2 2016 159

Multiple Sclerosis - Pipeline by Compugen Ltd, H2 2016 160

Multiple Sclerosis - Pipeline by Connexios Life Sciences Pvt Ltd, H2 2016 161

Multiple Sclerosis - Pipeline by Critical Outcome Technologies Inc, H2 2016 162

Multiple Sclerosis - Pipeline by CuraVac Inc, H2 2016 163

Multiple Sclerosis - Pipeline by Cyxone AB, H2 2016 164

Multiple Sclerosis - Pipeline by Daiichi Sankyo Company Ltd, H2 2016 165

Multiple Sclerosis - Pipeline by Dimerix Bioscience Pty Ltd, H2 2016 166

Multiple Sclerosis - Pipeline by Dong-A Socio Holdings Co Ltd, H2 2016 167

Multiple Sclerosis - Pipeline by Eisai Co Ltd, H2 2016 168

Multiple Sclerosis - Pipeline by Eli Lilly and Company, H2 2016 169

Multiple Sclerosis - Pipeline by Endece LLC, H2 2016 170

Multiple Sclerosis - Pipeline by Evgen Pharma Plc, H2 2016 171

Multiple Sclerosis - Pipeline by Evotec AG, H2 2016 172

Multiple Sclerosis - Pipeline by F. Hoffmann-La Roche Ltd, H2 2016 173

Multiple Sclerosis - Pipeline by Flex Pharma Inc, H2 2016 174

Multiple Sclerosis - Pipeline by Forward Pharma A/S, H2 2016 175

Multiple Sclerosis - Pipeline by FPRT Bio Inc, H2 2016 176

Multiple Sclerosis - Pipeline by Gemac SA, H2 2016 177

Multiple Sclerosis - Pipeline by Genervon Biopharmaceuticals LLC, H2 2016 178

Multiple Sclerosis - Pipeline by GeNeuro SA, H2 2016 179

Multiple Sclerosis - Pipeline by Genzyme Corp, H2 2016 180

Multiple Sclerosis - Pipeline by GlaxoSmithKline Plc, H2 2016 181

Multiple Sclerosis - Pipeline by Glenmark Pharmaceuticals Ltd, H2 2016 182

Multiple Sclerosis - Pipeline by Glialogix Inc, H2 2016 183

Multiple Sclerosis - Pipeline by Hansa Medical AB, H2 2016 184

Multiple Sclerosis - Pipeline by Harbor Therapeutics Inc, H2 2016 185

Multiple Sclerosis - Pipeline by HitGen LTD, H2 2016 186

Multiple Sclerosis - Pipeline by Humabs BioMed SA, H2 2016 187

Multiple Sclerosis - Pipeline by Hutchison MediPharma Ltd, H2 2016 188

Multiple Sclerosis - Pipeline by Iltoo Pharma, H2 2016 189

Multiple Sclerosis - Pipeline by Immune Response BioPharma Inc, H2 2016 190

Multiple Sclerosis - Pipeline by Immune Therapeutics Inc, H2 2016 191

Multiple Sclerosis - Pipeline by ImmuNext Inc, H2 2016 192

Multiple Sclerosis - Pipeline by Immungenetics AG, H2 2016 193

Multiple Sclerosis - Pipeline by Inception Sciences Inc, H2 2016 194

Multiple Sclerosis - Pipeline by Innate Immunotherapeutics Ltd, H2 2016 195

Multiple Sclerosis - Pipeline by Inovio Pharmaceuticals Inc, H2 2016 196

Multiple Sclerosis - Pipeline by Io Therapeutics Inc, H2 2016 197

Multiple Sclerosis - Pipeline by Jyant Technologies Inc, H2 2016 198

Multiple Sclerosis - Pipeline by Kadimastem Ltd, H2 2016 199

Multiple Sclerosis - Pipeline by Kadmon Corp LLC, H2 2016 200

Multiple Sclerosis - Pipeline by KAHR medical Ltd, H2 2016 201

Multiple Sclerosis - Pipeline by KaloBios Pharmaceuticals Inc, H2 2016 202

Multiple Sclerosis - Pipeline by Kancera AB, H2 2016 203

Multiple Sclerosis - Pipeline by Kareus Therapeutics SA, H2 2016 204

Multiple Sclerosis - Pipeline by Karo Pharma AB, H2 2016 205

Multiple Sclerosis - Pipeline by Karyopharm Therapeutics Inc, H2 2016 206

Multiple Sclerosis - Pipeline by Kissei Pharmaceutical Co Ltd, H2 2016 207

Multiple Sclerosis - Pipeline by KPI Therapeutics Inc, H2 2016 208

Multiple Sclerosis - Pipeline by Kyorin Pharmaceutical Co Ltd, H2 2016 209

Multiple Sclerosis - Pipeline by Lead Discovery Center GmbH, H2 2016 210

Multiple Sclerosis - Pipeline by LFB SA, H2 2016 211

Multiple Sclerosis - Pipeline by Lipocure Ltd, H2 2016 212

Multiple Sclerosis - Pipeline by MacroGenics Inc, H2 2016 213

Multiple Sclerosis - Pipeline by MAKScientific LLC, H2 2016 214

Multiple Sclerosis - Pipeline by Mapi Pharma Ltd, H2 2016 215

Multiple Sclerosis - Pipeline by Marathon Pharmaceuticals LLC, H2 2016 216

Multiple Sclerosis - Pipeline by MedAnnex Ltd, H2 2016 217

Multiple Sclerosis - Pipeline by MedDay SA, H2 2016 218

Multiple Sclerosis - Pipeline by Medestea Research & Production SpA, H2 2016 219

Multiple Sclerosis - Pipeline by MedImmune LLC, H2 2016 220

Multiple Sclerosis - Pipeline by Merck KGaA, H2 2016 221

Multiple Sclerosis - Pipeline by Meta-IQ ApS, H2 2016 222

Multiple Sclerosis - Pipeline by Mitochon Pharmaceuticals Inc, H2 2016 223

Multiple Sclerosis - Pipeline by Mitsubishi Tanabe Pharma Corp, H2 2016 224

Multiple Sclerosis - Pipeline by MorphoSys AG, H2 2016 225

Multiple Sclerosis - Pipeline by Mount Tam Biotechnologies Inc, H2 2016 226

Multiple Sclerosis - Pipeline by Neuralstem Inc, H2 2016 227

Multiple Sclerosis - Pipeline by Neuren Pharmaceuticals Ltd, H2 2016 228

Multiple Sclerosis - Pipeline by Neuronax SAS, H2 2016 229

Multiple Sclerosis - Pipeline by Neurotec Pharma SL, H2 2016 230

Multiple Sclerosis - Pipeline by New World Laboratories Inc, H2 2016 231

Multiple Sclerosis - Pipeline by Novartis AG, H2 2016 232

Multiple Sclerosis - Pipeline by NovImmune SA, H2 2016 233

Multiple Sclerosis - Pipeline by Nuevolution AB, H2 2016 234

Multiple Sclerosis - Pipeline by Ogeda SA, H2 2016 235

Multiple Sclerosis - Pipeline by Omeros Corp, H2 2016 236

Multiple Sclerosis - Pipeline by OncoImmune Inc, H2 2016 237

Multiple Sclerosis - Pipeline by Opexa Therapeutics Inc, H2 2016 238

Multiple Sclerosis - Pipeline by Oryzon Genomics SA, H2 2016 239

Multiple Sclerosis - Pipeline by OSE Immunotherapeutics, H2 2016 240

Multiple Sclerosis - Pipeline by Parvus Therapeutics Inc, H2 2016 241

Multiple Sclerosis - Pipeline by Peptinov SAS, H2 2016 242

Multiple Sclerosis - Pipeline by Pfenex Inc, H2 2016 243

Multiple Sclerosis - Pipeline by Pfizer Inc, H2 2016 244

Multiple Sclerosis - Pipeline by PharmaEssentia Corp, H2 2016 245

Multiple Sclerosis - Pipeline by PharmatrophiX Inc, H2 2016 246

Multiple Sclerosis - Pipeline by Pharmaxis Ltd, H2 2016 247

Multiple Sclerosis - Pipeline by Pieris Pharmaceuticals Inc, H2 2016 248

Multiple Sclerosis - Pipeline by Polleo Pharma Ltd, H2 2016 249

Multiple Sclerosis - Pipeline by ProNoxis AB, H2 2016 250

Multiple Sclerosis - Pipeline by Prothena Corp Plc, H2 2016 251

Multiple Sclerosis - Pipeline by Q Therapeutics Inc, H2 2016 252

Multiple Sclerosis - Pipeline by ReceptoPharm Inc, H2 2016 253

Multiple Sclerosis - Pipeline by RedHill Biopharma Ltd, H2 2016 254

Multiple Sclerosis - Pipeline by RegeneRx Biopharmaceuticals Inc, H2 2016 255

Multiple Sclerosis - Pipeline by Regenesance BV, H2 2016 256

Multiple Sclerosis - Pipeline by Renovo Neural Inc, H2 2016 257

Multiple Sclerosis - Pipeline by Resverlogix Corp, H2 2016 258

Multiple Sclerosis - Pipeline by ReveraGen BioPharma Inc, H2 2016 259

Multiple Sclerosis - Pipeline by Rigel Pharmaceuticals Inc, H2 2016 260

Multiple Sclerosis - Pipeline by Rodos BioTarget GmbH, H2 2016 261

Multiple Sclerosis - Pipeline by SanBio Inc, H2 2016 262

Multiple Sclerosis - Pipeline by Santhera Pharmaceuticals Holding AG, H2 2016 263

Multiple Sclerosis - Pipeline by Sareum Holdings Plc, H2 2016 264

Multiple Sclerosis - Pipeline by Sorrento Therapeutics Inc, H2 2016 265

Multiple Sclerosis - Pipeline by Symic Biomedical Inc, H2 2016 266

Multiple Sclerosis - Pipeline by Synthon Holdings BV, H2 2016 267

Multiple Sclerosis - Pipeline by Targazyme Inc, H2 2016 268

Multiple Sclerosis - Pipeline by Teikoku Pharma USA Inc, H2 2016 269

Multiple Sclerosis - Pipeline by Teva Pharmaceutical Industries Ltd, H2 2016 270

Multiple Sclerosis - Pipeline by Therapix Biosciences Ltd, H2 2016 271

Multiple Sclerosis - Pipeline by TikoMed AB, H2 2016 272

Multiple Sclerosis - Pipeline by Toleranzia AB, H2 2016 273

Multiple Sclerosis - Pipeline by Topas Therapeutics GmbH, H2 2016 274

Multiple Sclerosis - Pipeline by TxCell SA, H2 2016 275

Multiple Sclerosis - Pipeline by Vaccinex Inc, H2 2016 276

Multiple Sclerosis - Pipeline by Vakzine Projekt Management GmbH, H2 2016 277

Multiple Sclerosis - Pipeline by Virogenomics BioDevelopment Inc, H2 2016 278

Multiple Sclerosis - Pipeline by Vitae Pharmaceuticals Inc, H2 2016 279

Multiple Sclerosis - Pipeline by VivaCell Biotechnology Espana SL, H2 2016 280

Multiple Sclerosis - Pipeline by Xenetic Biosciences (UK) Ltd, H2 2016 281

Multiple Sclerosis - Pipeline by XL-protein GmbH, H2 2016 282

Multiple Sclerosis - Pipeline by Yungjin Pharm Co Ltd, H2 2016 283

Multiple Sclerosis - Pipeline by Zenith Capital Corp, H2 2016 284

Multiple Sclerosis - Pipeline by Zydus Cadila Healthcare Ltd, H2 2016 285

Assessment by Monotherapy Products, H2 2016 286

Assessment by Combination Products, H2 2016 287

Number of Products by Stage and Target, H2 2016 289

Number of Products by Stage and Mechanism of Action, H2 2016 305

Number of Products by Stage and Route of Administration, H2 2016 324

Number of Products by Stage and Molecule Type, H2 2016 326

Multiple Sclerosis - Dormant Projects, H2 2016 875

Multiple Sclerosis - Dormant Projects (Contd..1), H2 2016 876

Multiple Sclerosis - Dormant Projects (Contd..2), H2 2016 877

Multiple Sclerosis - Dormant Projects (Contd..3), H2 2016 878

Multiple Sclerosis - Dormant Projects (Contd..4), H2 2016 879

Multiple Sclerosis - Dormant Projects (Contd..5), H2 2016 880

Multiple Sclerosis - Dormant Projects (Contd..6), H2 2016 881

Multiple Sclerosis - Dormant Projects (Contd..7), H2 2016 882

Multiple Sclerosis - Dormant Projects (Contd..8), H2 2016 883

Multiple Sclerosis - Dormant Projects (Contd..9), H2 2016 884

Multiple Sclerosis - Dormant Projects (Contd..10), H2 2016 885

Multiple Sclerosis - Dormant Projects (Contd..11), H2 2016 886

Multiple Sclerosis - Dormant Projects (Contd..12), H2 2016 887

Multiple Sclerosis - Dormant Projects (Contd..13), H2 2016 888

Multiple Sclerosis - Dormant Projects (Contd..14), H2 2016 889

Multiple Sclerosis - Dormant Projects (Contd..15), H2 2016 890

Multiple Sclerosis - Dormant Projects (Contd..16), H2 2016 891

Multiple Sclerosis - Dormant Projects (Contd..17), H2 2016 892

Multiple Sclerosis - Dormant Projects (Contd..18), H2 2016 893

Multiple Sclerosis - Dormant Projects (Contd..19), H2 2016 894

Multiple Sclerosis - Dormant Projects (Contd..20), H2 2016 895

Multiple Sclerosis - Dormant Projects (Contd..21), H2 2016 896

Multiple Sclerosis - Dormant Projects (Contd..22), H2 2016 897

Multiple Sclerosis - Dormant Projects (Contd..23), H2 2016 898

Multiple Sclerosis - Dormant Projects (Contd..24), H2 2016 899

Multiple Sclerosis - Discontinued Products, H2 2016 900

Multiple Sclerosis - Discontinued Products (Contd..1), H2 2016 901

Multiple Sclerosis - Discontinued Products (Contd..2), H2 2016 902

Multiple Sclerosis - Discontinued Products (Contd..3), H2 2016 903

Multiple Sclerosis - Discontinued Products (Contd..4), H2 2016 90

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@] kenresearch.com
 

2-BBB Medicines BV, 4D Pharma Plc, AB Science SA, AbbVie Inc, Abion Inc, Ablynx NV, Abzena Plc, Acorda Therapeutics Inc, Actelion Ltd, Adamas Pharmaceuticals Inc, Addex Therapeutics Ltd, Adhaere Pharmaceuticals Inc, Aegis Therapeutics LLC, Affectis Pharmaceuticals AG, AiCuris GmbH & Co KG, Alkermes Plc, Alpha Cancer Technologies Inc, Amarna Therapeutics BV, Anavex Life Sciences Corp, Antisense Therapeutics Ltd, Aphios Corp, Apitope International NV, ARA Healthcare Pvt Ltd, Arena Pharmaceuticals Inc, arGEN-X BV, Argos Therapeutics Inc, Arrien Pharmaceuticals LLC, Artielle ImmunoTherapeutics Inc, Astellas Pharma Inc, Asterias Biotherapeutics Inc, Atara Biotherapeutics Inc, Athersys Inc, Atlantic Bio Sci LLC, Axxam SpA, Baliopharm AG, Bio-Cancer Treatment International Ltd, BioAegis Therapeutics Inc, BioApex sro, Biocad, Biocon Ltd, Biogen Inc, Biogenomics Ltd, BioHealthonomics Inc, Biokine Therapeutics Ltd, Biomar Microbial Technologies, Bioncotech Therapeutics SL, Bionovis SA, Bionure Farma SL, Biovista Inc, Bolder Biotechnology Inc, BrainStorm Cell Therapeutics Inc, Bristol-Myers Squibb Company, C4X Discovery Holdings PLC, CASI Pharmaceuticals Inc, Catalyst Pharmaceuticals Inc, Celgene Corp, Cell Cure Neurosciences Ltd, Cell2B Advanced Therapeutics SA, Cellceutix Corp, Cognosci Inc, Coherus BioSciences Inc, Commence Bio Inc, Compugen Ltd, Connexios Life Sciences Pvt Ltd, Critical Outcome Technologies Inc, CuraVac Inc, Cyxone AB, Daiichi Sankyo Company Ltd, Dimerix Bioscience Pty Ltd, Dong-A Socio Holdings Co Ltd, Eisai Co Ltd, Eli Lilly and Company, Endece LLC, Evgen Pharma Plc, Evotec AG, F. Hoffmann-La Roche Ltd, Flex Pharma Inc, Forward Pharma A/S, FPRT Bio Inc, Gemac SA, Genervon Biopharmaceuticals LLC, GeNeuro SA, Genzyme Corp, GlaxoSmithKline Plc, Glenmark Pharmaceuticals Ltd, Glialogix Inc, Hansa Medical AB, Harbor Therapeutics Inc, HitGen LTD, Humabs BioMed SA, Hutchison MediPharma Ltd, Iltoo Pharma, Immune Response BioPharma Inc, Immune Therapeutics Inc, ImmuNext Inc, Immungenetics AG, Inception Sciences Inc, Innate Immunotherapeutics Ltd, Inovio Pharmaceuticals Inc, Io Therapeutics Inc, Jyant Technologies Inc, Kadimastem Ltd, Kadmon Corp LLC, KAHR medical Ltd, KaloBios Pharmaceuticals Inc, Kancera AB, Kareus Therapeutics SA, Karo Pharma AB, Karyopharm Therapeutics Inc, Kissei Pharmaceutical Co Ltd, KPI Therapeutics Inc, Kyorin Pharmaceutical Co Ltd, Lead Discovery Center GmbH, LFB SA, Lipocure Ltd, MacroGenics Inc, MAKScientific LLC, Mapi Pharma Ltd, Marathon Pharmaceuticals LLC, MedAnnex Ltd, MedDay SA, Medestea Research & Production SpA, MedImmune LLC, Merck KGaA, Meta-IQ ApS, Mitochon Pharmaceuticals Inc, Mitsubishi Tanabe Pharma Corp, MorphoSys AG, Mount Tam Biotechnologies Inc, Neuralstem Inc, Neuren Pharmaceuticals Ltd, Neuronax SAS, Neurotec Pharma SL, New World Laboratories Inc, Novartis AG, NovImmune SA, Nuevolution AB, Ogeda SA, Omeros Corp, OncoImmune Inc, Opexa Therapeutics Inc, Oryzon Genomics SA, OSE Immunotherapeutics, Parvus Therapeutics Inc, Peptinov SAS, Pfenex Inc, Pfizer Inc, PharmaEssentia Corp, PharmatrophiX Inc, Pharmaxis Ltd, Pieris Pharmaceuticals Inc, Polleo Pharma Ltd, ProNoxis AB, Prothena Corp Plc, Q Therapeutics Inc, ReceptoPharm Inc, RedHill Biopharma Ltd, RegeneRx Biopharmaceuticals Inc, Regenesance BV, Renovo Neural Inc, Resverlogix Corp, ReveraGen BioPharma Inc, Rigel Pharmaceuticals Inc, Rodos BioTarget GmbH, SanBio Inc, Santhera Pharmaceuticals Holding AG, Sareum Holdings Plc, Sorrento Therapeutics Inc, Symic Biomedical Inc, Synthon Holdings BV, Targazyme Inc, Teikoku Pharma USA Inc, Teva Pharmaceutical Industries Ltd, Therapix Biosciences Ltd, TikoMed AB, Toleranzia AB, Topas Therapeutics GmbH, TxCell SA, Vaccinex Inc, Vakzine Projekt Management GmbH, Virogenomics BioDevelopment Inc, Vitae Pharmaceuticals Inc, VivaCell Biotechnology Espana SL, Xenetic Biosciences (UK) Ltd, XL-protein GmbH, Yungjin Pharm Co Ltd, Zenith Capital Corp, Zydus Cadila Healthcare Ltd

select a license
Single User License
USD 2500 INR 179450
Site License
USD 5000 INR 358900
Corporate User License
USD 7500 INR 538350

NEWSLETTER BY CATEGORY




Testimonials

An excellent provider. Thorough, precise and outstanding insight. They drill down to what we need and their reports are effective at integrating text with supporting graphics and charts. Their reports are a great resource to go back too. ...

Coherent, high-quality, thoroughly-researched reports. We received a very quick response to all our queries which eventually expedited the entire process....

Well structured, the insights they shared with us were very helpful and reliable. Their timely assistance make their services invaluable to us. I would highly recommend them and would definitely use them again in the future if needed...

The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements....

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ...



Ken Research Private Limited, Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

sales [@] kenresearch.com